Vidofludimus calcium by Immunic for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Moderna sticks to long-term strategy in first-quarter update, ends pact with Metagenomi

Moderna’s shift to a more “restrained” posture was on full display Thursday morning during its first-quarter earnings update. CEO Stéphane Bancel and his team stayed

May 3, 2024

GH Research’s Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s GHRS Investigational New Drug (IND) application for a Phase 1 clinical trial of

October 3, 2023

Carbon Health CEO Eren Bali steps down

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.